Literature DB >> 11090186

Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Q X Hu1, A P Barry, Z X Wang, S M Connolly, S C Peiper, M L Greenberg.   

Abstract

The evolution of human immunodeficiency virus type 1 infection is associated with a shift in the target cell population, driven by variability in coreceptor utilization resulting from diversity in env. To elucidate the potential consequences of these changes for Env-mediated fusion over the course of AIDS, we examined the biological properties of serial viral isolates and determined coreceptor utilization by the products of env cloned from two individuals, followed from the detection of seroconversion throughout the course of their infection. One had a typical course, and the other had an accelerated progression. Early isolates were non-syncytium inducing, and the corresponding Env exclusively utilized CCR5, whereas Env from late phases of infection showed restricted utilization of CXCR4 in both patients. Env from subject SC24, who had a standard progression, demonstrated multitropism, manifested by utilization of CCR3, CXCR4, and CCR5 in the intervening period. In contrast, Env from patient SC51, who experienced early conversion to the syncytium-inducing phenotype, developed dualtropic coreceptor utilization of CCR5 and CXCR4. Genetic analysis of env from each isolate revealed that those with an X4 phenotype formed a distinct subcluster within each subject. Analysis of chimeras constructed from R5 and multispecific env from patient SC24 demonstrated that while the V3 domain played a dominant role in determining coreceptor utilization, sequences in the V4-V5 region also contributed to the latter phenotype. Immunoprecipitation experiments confirmed that the hybrid Env proteins were expressed at similar levels. These experiments demonstrate that progression from the R5 to X4 phenotype may occur through a multi- or dual-tropic intermediate and that multiple domains contribute to this process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090186      PMCID: PMC112469          DOI: 10.1128/jvi.74.24.11858-11872.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

2.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  CCR5 HIV-1 coreceptor activity. Role of cooperativity between residues in N-terminal extracellular and intracellular domains.

Authors:  Z Wang; B Lee; J L Murray; F Bonneau; Y Sun; V Schweickart; T Zhang; S C Peiper
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

5.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression.

Authors:  A M de Roda Husman; R P van Rij; H Blaak; S Broersen; H Schuitemaker
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

7.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Complex determinants of macrophage tropism in env of simian immunodeficiency virus.

Authors:  K Mori; D J Ringler; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.

Authors:  M Koot; A H Vos; R P Keet; R E de Goede; M W Dercksen; F G Terpstra; R A Coutinho; F Miedema; M Tersmette
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

10.  A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.

Authors:  J P Moore; Q J Sattentau; P J Klasse; L C Burkly
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

View more
  37 in total

1.  Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.

Authors:  Guity Ghaffari; Daniel L Tuttle; Daniel Briggs; Brant R Burkhardt; Deepa Bhatt; Warren A Andiman; John W Sleasman; Maureen M Goodenow
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

3.  Reduced monomeric CD4 is the preferred receptor for HIV.

Authors:  Lisa J Matthias; Iman Azimi; Catherine A Tabrett; Philip J Hogg
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

4.  Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.

Authors:  K Tokunaga; M L Greenberg; M A Morse; R I Cumming; H K Lyerly; B R Cullen
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization.

Authors:  Qinxue Hu; Naheed Mahmood; Robin J Shattock
Journal:  Virology       Date:  2007-07-23       Impact factor: 3.616

6.  Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Authors:  John J Dwyer; Karen L Wilson; Donna K Davison; Stephanie A Freel; Jennifer E Seedorff; Stephen A Wring; Nicolai A Tvermoes; Thomas J Matthews; Michael L Greenberg; Mary K Delmedico
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-19       Impact factor: 11.205

7.  Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.

Authors:  John J Dwyer; Karen L Wilson; Kimberly Martin; Jennifer E Seedorff; Aisha Hasan; Robyn J Medinas; Donna K Davison; Michael D Feese; Hans-Thomas Richter; Hidong Kim; Thomas J Matthews; Mary K Delmedico
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

8.  Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.

Authors:  Ronald S Veazey; Thomas A Ketas; Per Johan Klasse; Donna K Davison; Morgan Singletary; Linda C Green; Michael L Greenberg; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-22       Impact factor: 11.205

9.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

10.  Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes.

Authors:  Zaher Hanna; Elena Priceputu; Pavel Chrobak; Chunyan Hu; Véronique Dugas; Mathieu Goupil; Miriam Marquis; Louis de Repentigny; Paul Jolicoeur
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.